Other languages Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 02:34:42 2024-04-19 am EDT			5-day change	1st Jan Change
4,636 ^JPY	+2.20%		+2.39%	+19.73%

12:39pm	Middle East Tensions Dent Asian Stock Markets	MT
Apr. 10	Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Middle East Tensions Dent Asian Stock Markets	06:39am
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10
Roche erhält CE-Kennung für erstes Brustkrebs-Begleitdiagnostikum	Apr. 10
Scholz setzt auf weitere Pharma-Investitionen in Deutschland	Apr. 08
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	Apr. 08
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	Apr. 08
AstraZeneca : approbation étendue pour Enhertu aux USA	Apr. 08
AstraZeneca hails neurological data for Ultomiris, Soliris	Apr. 08
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	Apr. 08
Astra hails neurology data; CVS flags cyberattack	Apr. 08
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	Apr. 08
Les valeurs à suivre à Paris et en Europe (actualisé)	Apr. 08
AstraZeneca Wins US Approval for Solid Tumor Treatment	Apr. 07
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	Apr. 05
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	Apr. 05
Un séisme de magnitude 6,0 secoue le nord-est du Japon, pas d'alerte au tsunami	Apr. 04
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03
Merck : 1ère patiente dans une étude sur raludotatug	Apr. 03
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03
AstraZeneca, Daiichi make US progress with licence approvals	Apr. 03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Other languages

Filters